---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-015597"
form_type: "8-K"
ticker: "ALKS"
cik: "0001520262"
company_name: "Alkermes plc."
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T01:10:55.537872+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alkermes reports 2023 total revenues $1.66B, GAAP EPS $2.10; guides 2024 EBITDA ~$445-485M

## Summary
- GAAP net income $355.8M vs loss of $158.3M in 2022; diluted EPS $2.10.
- Proprietary net sales $920M (+18% YoY); LYBALVI grew to $191.9M (up 100% YoY).
- 2024 guidance: total rev $1.5-1.6B, GAAP net income $350-390M, non-GAAP net income $465-505M.
- Board approved new $400M share repurchase program (no expiration date).
- Oncology separation completed Nov 2023; Athlone facility sale to Novo Nordisk for $92.5M expected mid-2024.

## SEC filing metadata
- accession: 0000950170-24-015597
- form_type: 8-K
- ticker: ALKS
- cik: 0001520262
- company_name: Alkermes plc.
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1520262/000095017024015597/0000950170-24-015597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1520262/000095017024015597/alks-20240215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-015597
- JSON: https://secwatch.observer/filing/0000950170-24-015597.json
- Plain text: https://secwatch.observer/filing/0000950170-24-015597.txt

## Key facts
- Earnings Releases
  Alkermes plc. reported the quarter and year ended Dec. 31, 2023 results: revenue $1,663.4 million, net income $355.8 million, EPS $2.10. Guidance initiated.
  - Period: the quarter and year ended Dec. 31, 2023
  - Revenue: $1,663.4 million
  - Net income: $355.8 million
  - EPS: $2.10
  - Guidance: initiated
  - Result: reported results
  source text: Joyce +1 781 249 8927 Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024 — Total Revenues of $1.66 Billion in 2023; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income of $356 Million and Diluted GAAP Earnings per Share of $2.10 for 2023 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1520262/000095017024015597/0000950170-24-015597-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.